A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277
Recruiting
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits. Participants who have completed the primary 72-week GPIX study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the o... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
08/15/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +1 locations
Conditions: Obesity, Weight Gain
Register for Updates
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
NCT06373146
Active Not Recruiting
The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Velocity Clinical Research, Gardena, Gardena, California +6 locations
Conditions: Obesity
Register for Updates
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
NCT06588283
Active Not Recruiting
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: California Dermatology & Clinical Research Institute, Encinitas, California +8 locations
Conditions: Psoriasis, Obesity
Register for Updates
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
NCT04184622
Completed
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: John Muir Physician Network Clinical Research Center, Concord, California +5 locations
Conditions: Overweight, Obesity
Register for Updates
Tirzepatide for Alcohol Use Disorder
NCT06994338
Not Yet Recruiting
The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or obesity.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
05/24/2025
Locations: Keck School of Medicine, University of Southern California, Los Angeles, California
Conditions: Alcohol Use Disorder, Obesity and Overweight
Register for Updates
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06047548
Active Not Recruiting
The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Velocity Clinical Research, Westlake, Los Angeles, California +2 locations
Conditions: Overweight, Obesity
Register for Updates
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
NCT05433584
Active Not Recruiting
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: San Fernando Valley Health Institute, Canoga Park, California +9 locations
Conditions: Type 2 Diabetes
Register for Updates
Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over
NCT06515418
Terminated
This study aims to find out how well a combination of oral azelaprag taken once a day (QD) or twice a day (BID), along with a weekly injection of tirzepatide, works for weight management in adults 55 years and older. The researchers are also looking at safety. Estimated Study Length: * with the optional prescreening, the study duration may be up to 48 weeks. * the treatment duration will be 24 weeks followed by 12 weeks follow-up. * the visit frequency will be every 2 weeks for the first 8 wee... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
03/11/2025
Locations: Site 107, Los Angeles, California +2 locations
Conditions: Obesity
Register for Updates
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
NCT05260021
Completed
The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both. The overall study will last about 60 weeks with up to 14 clinic visits and 6 phone visits. Clinic visits will include blood sample collection, physical exam and questionnaire.
Gender:
ALL
Ages:
Between 10 years and 18 years
Trial Updated:
02/24/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +3 locations
Conditions: Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
Register for Updates
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
NCT04166773
Completed
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/22/2025
Locations: Fresno Clinical Research Center, Fresno, California +8 locations
Conditions: Nonalcoholic Steatohepatitis
Register for Updates
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
NCT06732245
Not Yet Recruiting
A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
Gender:
ALL
Ages:
Between 19 years and 80 years
Trial Updated:
12/12/2024
Locations: Biomed Research Unit #90067-102, Los Angeles, California +2 locations
Conditions: Obesity and Overweight
Register for Updates
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
NCT05706506
Completed
The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in participants with type 2 diabetes (T2D).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: New Hope Research Development, Corona, California +7 locations
Conditions: Type 2 Diabetes, Diabetes Mellitus, Type 2
Register for Updates